Cargando…
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006894/ https://www.ncbi.nlm.nih.gov/pubmed/27622011 http://dx.doi.org/10.1080/2162402X.2015.1052212 |